| Title: |
Effects of β2-receptor stimulation by indacaterol in chronic heart failure treated with selective or non-selective β-blockers: a randomized trial |
| Authors: |
Contini, Mauro; Spadafora, Emanuele; Barbieri, Simone; Gugliandolo, Paola; Salvioni, Elisabetta; Magini, Alessandra; Apostolo, Anna; Palermo, Pietro; Alimento, Marina; Agostoni, Piergiuseppe |
| Contributors: |
M. Contini; E. Spadafora; S. Barbieri; P. Gugliandolo; E. Salvioni; A. Magini; A. Apostolo; P. Palermo; M. Alimento; P. Agostoni |
| Publisher Information: |
Nature Publishing Group |
| Publication Year: |
2020 |
| Collection: |
The University of Milan: Archivio Istituzionale della Ricerca (AIR) |
| Subject Terms: |
Settore MED/11 - Malattie dell'Apparato Cardiovascolare |
| Description: |
Alveolar β2-receptor blockade worsens lung diffusion in heart failure (HF). This effect could be mitigated by stimulating alveolar β2-receptors. We investigated the safety and the effects of indacaterol on lung diffusion, lung mechanics, sleep respiratory behavior, cardiac rhythm, welfare, and exercise performance in HF patients treated with a selective (bisoprolol) or a non-selective (carvedilol) β-blocker. Study procedures were performed before and after indacaterol and placebo treatments according to a cross-over, randomized, double-blind protocol in forty-four patients (27 on bisoprolol and 17 on carvedilol). No differences between indacaterol and placebo were observed in the whole population except for a significantly higher VE/VCO2 slope and lower maximal PETCO2 during exercise with indacaterol, entirely due to the difference in the bisoprolol group (VE/VCO2 31.8 ± 5.9 vs. 28.5 ± 5.6, p < 0.0001 and maximal PETCO2 36.7 ± 5.5 vs. 37.7 ± 5.8 mmHg, p < 0.02 with indacaterol and placebo, respectively). In carvedilol, indacaterol was associated with a higher peak heart rate (119 ± 34 vs. 113 ± 30 bpm, with indacaterol and placebo) and a lower prevalence of hypopnea during sleep (3.8 [0.0;6.3] vs. 5.8 [2.9;10.5] events/hour, with indacaterol and placebo). Inhaled indacaterol is well tolerated in HF patients, it does not influence lung diffusion, and, in bisoprolol, it increases ventilation response to exercise. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/32345990; info:eu-repo/semantics/altIdentifier/wos/WOS:000560712400002; volume:10; issue:1; journal:SCIENTIFIC REPORTS; https://hdl.handle.net/2434/743298 |
| DOI: |
10.1038/s41598-020-62644-1 |
| Availability: |
https://hdl.handle.net/2434/743298; https://doi.org/10.1038/s41598-020-62644-1 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.331F7BFF |
| Database: |
BASE |